U.S. markets closed

Lipocine Inc. (LPCN)

NasdaqCM - NasdaqCM Real Time Price. Currency in USD
Add to watchlist
0.4500+0.0146 (+3.35%)
At close: 04:00PM EDT
0.4592 +0.01 (+2.04%)
After hours: 07:08PM EDT
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Bullishpattern detected
Fast Stochastic

Fast Stochastic

Previous Close0.4354
Bid0.4300 x 1000
Ask0.4592 x 1200
Day's Range0.4300 - 0.4582
52 Week Range0.3610 - 1.8900
Avg. Volume258,880
Market Cap39.83M
Beta (5Y Monthly)N/A
PE Ratio (TTM)11.25
Earnings DateNov 08, 2022 - Nov 14, 2022
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est3.33
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
Near Fair Value
4% Est. Return

Subscribe to Yahoo Finance Plus to view Fair Value for LPCN

View details
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
  • Lipocine Inc.
    Daily Spotlight: VIX Back to 30Fear has returned to the equity market, as inflation readings have failed to cool dramatically, the Federal Reserve remains on a long-term course toward higher rates, U.S. mid-term elections approach, Vladimir Putin threatens the use of nuclear weapons in Eastern Europe, and the global economy reels toward recession. The VIX Volatility Index is a key gauge of investor sentiment and has been elevated above 20 for most of the past two years. Last Friday, after a 486-point drop in the Dow Jones Industrial Average, the VIX closed at 29.92 after touching 32 earlier in the day. A little more than a month ago, the VIX was below 20, and seemingly headed lower as the U.S. consumer economy appeared to be in good shape. How can the market turn so quickly? Investors are always looking ahead, and the latest data (the CPI two weeks ago, the Fed's 75-basis-point hike last week) point toward near-term challenges for the economy, companies, and corporate earnings. New data will be out this week (the Fed's favorite inflation gauge, the PCE indices) and corporate earnings reports will start to flow in mid-October. We expect volatility to remain high, yet the pullback in stock prices unearths some attractive valuations. Buy low and sell high. We think investors should continue to focus on well-managed companies with clear growth objectives and clean balance sheets.
    Fair Value
    Economic Moat
    5 days agoArgus Research
View more
  • PR Newswire

    Lipocine to Participate in the Cantor Neurology & Psychiatric Conference

    Lipocine Inc. (NASDAQ: LPCN), a biopharmaceutical company focused on leveraging its proprietary Lip'ral platform to develop differentiated products through the oral delivery of previously difficult to deliver molecules focused on treating CNS disorders, announced today that it will participate in the Cantor Neurology & Psychiatric Conference (October 6-7) in San Francisco.

  • Benzinga

    Lipocine To Focus On Central Nervous System Conditions; Explores Partnerships For Non-Core Assets

    Lipocine Inc (NASDAQ: LPCN) announced its plans to focus on treating Central Nervous System (CNS) disorders. The company's priority is to advance its endogenous neuroactive steroids (NAS) pipeline. The CNS development portfolio includes LPCN 1154, a fast-acting oral antidepressant for postpartum depression (PPD) with potential for outpatient use; LPCN 2101 for women with epilepsy; and additional undisclosed CNS-focused candidates. Lipocine's most advanced NAS candidate is LPCN 1154, a non-invasi

  • PR Newswire

    Lipocine Announces Strategic Realignment and Forward Focus on Treating CNS Disorders

    Lipocine Inc. (NASDAQ: LPCN), a biopharmaceutical company focused on leveraging its proprietary Lip'ral platform to develop differentiated products through the oral delivery of previously difficult to deliver molecules, announced today its plans to focus on treating CNS disorders.